Floatz logo

Dcc-3084

Castration-Resistant Prostate Cancer (CRPC)

Deciphera Pharmaceuticals, LLCPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

229 Active assets in the Castration-Resistant Prostate Cancer (CRPC) cohort.

Asset / SponsorPhaseRating
Darolutamide
Bayer
Phase 4BBB
Enzalutamide
Prostate Cancer Clinical Trials Consortium
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Ding-Wei Ye
Phase 4BBB
Darolutamide
Bayer
Phase 3BB
Bms-907351
Rana McKay, MD
Phase 3BB

View all 50 →

Same molecule, other indications

Dcc-3084 is also rated in:

RAF MutationDormant
CC
Indicative ·
43 / 100
View asset →
neurofibromatosis type 1Dormant
CC
Indicative ·
43 / 100
View asset →
BRAF Gene MutationDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →